David Holbrook

David Mark Anthony Holbrook currently works at Liver Group Charity, as Chairman from 2016, NK:IO Ltd., as Chairman, the University of Cambridge, as Director-Life Sciences, Frontier IP Group Plc, as Independent Director from 2023, Oxford BioDynamics Plc, as Independent Non-Executive Director from 2019, MTI Partners Ltd., as Venture Partner, Cambridge Enterprise Ltd., as Investment Manager (Life Sciences) from 2016, and Ryse Asset Management LLP, as Principal.
Dr. Holbrook also formerly worked at IP2IPO Innovations Ltd., as Chief Executive Officer, Myconostica Ltd., as Chairman in 2009, Finsbury Worldwide Pharmaceutical Trust Plc, as Non-Executive Director from 2009 to 2010, Hunter-Fleming Ltd., as Non-Executive Director, ApaTech Ltd., as Director, Onyvax Ltd., as Executive Director, Roche Holding (UK) Ltd., as Director-Business Development, Lein Applied Diagnostics Ltd., as Director from 2009 to 2016, Eykona Medical Ltd., as Non-Executive Director from 2010 to 2014, Worldwide Healthcare Trust Plc, as Senior Independent Non-Executive Director from 2016 to 2021, Glaxo Wellcome Plc, as Manager-Worldwide Business Development, GSK Plc, as Principal, Wellcome Plc, as Manager, Lifearc, as Head-Seed Funds from 2018 to 2021, and Ai2 Ltd., as Principal from 2003 to 2013.
Dr. Holbrook received his graduate degree from the University of Oxford and Masters Business Admin degree from Harvard Business School.